Skip to main content

Avalo Therapeutics, Inc.

corporate_fare Company Profile

Avalo Therapeutics, Inc.

Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. Its lead asset includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.

Exchange: NASDAQSector: Life Sciences

show_chartPrice Chart

Loading chart...

feed AVTX - Latest Insights

AVTX
Apr 28, 2026, 7:01 AM EDT
Filing Type: 8-K
Importance Score:
8
Avalo Therapeutics Secures Option to Reduce $15M Contingent Milestone Payment to $7.375M
Sentiment: Positive
View Wiseek Article
AVTX
Apr 28, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Avalo Therapeutics Buys Out $15M Milestone for $7.375M, Saving $7.6M
Sentiment: Positive
View Wiseek Article
AVTX
Apr 23, 2026, 7:00 AM EDT
Source: Wiseek News
Importance Score:
7
Avalo Therapeutics Q1'26 Revenue Estimate at $0, EPS Expected at ($1.18) Ahead of April 30 Release
Sentiment: Neutral
View Wiseek Article
AVTX
Apr 10, 2026, 4:01 PM EDT
Filing Type: DEF 14A
Importance Score:
7
Avalo Therapeutics Seeks Shareholder Approval for ESPP Extension and Board Reduction
Sentiment: Negative
View Wiseek Article
AVTX
Mar 27, 2026, 4:01 PM EDT
Filing Type: 8-K
Importance Score:
7
Two Directors Depart Avalo Therapeutics Board Amidst Financial Challenges
Sentiment: Negative
View Wiseek Article
AVTX
Mar 23, 2026, 7:02 AM EDT
Filing Type: 10-K
Importance Score:
8
Avalo Therapeutics Reports Widened 2025 Net Loss, Increased Cash Burn, and Significant Dilution Potential Amidst Insider Selling Plans
Sentiment: Negative
View Wiseek Article
AVTX
Mar 23, 2026, 7:01 AM EDT
Filing Type: 8-K
Importance Score:
7
Avalo Therapeutics Reports 2025 Financials, Extends Cash Runway into 2028, and Anticipates Key Phase 2 Data in Q2 2026
Sentiment: Positive
View Wiseek Article
AVTX
Mar 16, 2026, 4:39 PM EDT
Filing Type: 144
Importance Score:
7
Officer Files Intent to Sell $466K in Shares Following Option Exercise
Sentiment: Negative
View Wiseek Article
AVTX
Jan 12, 2026, 7:53 AM EST
Filing Type: 8-K
Importance Score:
8
Avalo Therapeutics Discloses $98M Cash, Extending Runway into 2028
Sentiment: Positive
View Wiseek Article
AVTX
Jan 08, 2026, 4:01 PM EST
Filing Type: S-3
Importance Score:
8
Avalo Therapeutics Files $750M Universal Shelf Registration, Signaling Substantial Future Dilution
Sentiment: Negative
View Wiseek Article